For example, while Saxenda and Wegovy are GLP-1s indicated solely for weight-loss, Ozempic (semaglutide) and Mounjaro are widely covered for diabetes
Chen and Zhou 2024
To that end, were curious whether LLY can accelerate orfos launch timeline, added Tewari
Advanced Kinomescale catalyticcascade interference and pathway reconstruction Ultraresolution receptor/ligand docking and conformationaltransition modelling UPR/ERstress, mitophagy, autophagy and oxidativestress crosstalk research Deep multiomics network reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics) Cytoskeletal tensionmapping, polymer turnover and mechanosignalling analytics Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling Machinelearning SAR/QSAR pipelines for predictive molecular optimisation Toxicodynamics & Hazard Spectrum Rapid ROS accumulation and antioxidantbuffer system collapse Mitochondrial fragmentation, membranepotential failure or ETC inhibition Severe Na/K/Ca ionhomeostasis disruption Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics membrane-integrity failure and lipidbilayer thinning NF-B, STAT and IRF inflammatoryaxis hyperactivation Engagement of multiaxis programmed-cell-death pathways Epigenetic drift across methylation/acetylation domains Only GMP materials will be supplied, logistics all according to GDP
How does bStrong support members on GLP-1 medications
Lilly has not announced a retatrutide brand name
